Physician profile
Thomas Chan
NPI 1932203312
$541.81
in general payments reported to CMS, 2019-2025
12 companies · $99.35 in 2025
The $99.35 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $44.92 · 2021: $37.47 · 2022: $21.12 · 2023: $15.30 · 2024: $113 · 2025: $99.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $148.83 | 2019-2024 | Vaxelis, Vaxneuvance, Gardasil |
| Novo Nordisk INC | $89.39 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $64.18 | 2019 | |
| Pfizer INC. | $60.02 | 2025 | |
| Shield Therapeutics INC | $35.99 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $24.01 | 2025 | Recorlev |
| Glaxosmithkline, LLC. | $23.15 | 2020 | |
| Avvisto Therapeutics, LLC | $22.34 | 2024 | Cycloset |
| Lilly USA, LLC | $21.77 | 2020 | |
| Tactile Systems Technology INC | $18.54 | 2019 | |
| Genentech USA, INC. | $17.53 | 2019 | |
| Alk-Abello, INC | $16.06 | 2024 | Grastek, Ragwitek, Odactra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.